Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Other

Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia.

Andrade et al. • 2012 • J Neural Transm (Vienna). 2012;119(3):337-44.

September 18, 2018
Neurology

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.

November 15, 2017
Oncology

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

Veneris et al • 2017 • Gynecol Oncol.

November 15, 2017
Hypercortisolism (Cushing syndrome)

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.

Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.

October 15, 2017
Metabolism, Other

The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness.

Moraitis et al. • 2017 • J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120.

September 21, 2017
Hypercortisolism (Cushing syndrome)

U500 Insulin Screening of Diabetic Patients Uncovers a Large Amount of Undiagnosed Hypercortisolism Consistent With Cushing’s Syndrome

Editorial Team • 2017 • Diabetes

January 15, 2017
Hypercortisolism (Cushing syndrome)

Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome.

Moraitis AG, Auchus RJ. • 2016 • Case Rep Endocrinol. 2016;2016:8453801.

November 15, 2016
Neurology

New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.

Pineau et al. • 2016 • Neurobiol Aging. 2016;45:109-122.

November 15, 2016
Hypercortisolism (Cushing syndrome)

Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis

Steffensen et al • 2016 • European Journal of Endocrinology

November 5, 2016
Hypercortisolism (Cushing syndrome)

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

Costa et al • 2016 • J Diabetes Complications.

October 15, 2016
Page 14 of 16«‹1213141516›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top